Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Silodosin

FDA-approved product (capsule, oral), marketed as Rapaflo, Silodosin.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Silodosin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
FDA pharmacologic class
alpha-Adrenergic Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Silodosin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Silodosin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

    NCT02106182 · start 2014-01-02

    Registered record
    Registry ID
    NCT02106182
    Conditions
    Nocturia; Benign Prostatic Hyperplasia
    Interventions
    Silodosin; Laboratory tests; 3-days voiding diary; 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01-02
    Completion
    2016-08-01
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturia; Benign Prostatic Hyperplasia
    InterventionSilodosin; Laboratory tests; 3-days voiding diary; 12 weeks
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation

    NCT02581826 · start 2013-10

    Registered record
    Registry ID
    NCT02581826
    Conditions
    Premature Ejaculation
    Interventions
    Silodosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-10
    Completion
    2016-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Ejaculation
    InterventionSilodosin; Placebo
    PhasePhase 2
    Registry statusUnknown

  • The Changes of Urine Growth Factors Level

    NCT06282731 · start 2013-05-31

    Registered record
    Registry ID
    NCT06282731
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-05-31
    Completion
    2017-04-27
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSilodosin
    PhaseEarly phase 1
    Registry statusCompleted

  • Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy

    NCT01560091 · start 2012-03

    Registered record
    Registry ID
    NCT01560091
    Conditions
    Kidney Stones
    Interventions
    silodosin; Extra-corporeal shock wave lithotripsy; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-03
    Completion
    2013-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    Interventionsilodosin; Extra-corporeal shock wave lithotripsy; Tamsulosin
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones

    NCT01533389 · start 2011-10

    Registered record
    Registry ID
    NCT01533389
    Conditions
    Ureteral Stone
    Interventions
    Silodosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-08
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteral Stone
    InterventionSilodosin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia

    NCT01757769 · start 2011-05

    Registered record
    Registry ID
    NCT01757769
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-08
    Enrolment
    1,036

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSilodosin
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

    NCT01228370 · start 2011-04

    Registered record
    Registry ID
    NCT01228370
    Conditions
    Neurogenic Bladder; Voiding Dysfunction
    Interventions
    silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-04
    Completion
    2012-01
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurogenic Bladder; Voiding Dysfunction
    Interventionsilodosin
    PhasePhase 4
    Registry statusCompleted

  • Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)

    NCT01259531 · start 2010-12

    Registered record
    Registry ID
    NCT01259531
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2011-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSilodosin
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH

    NCT01260129 · start 2010-10

    Registered record
    Registry ID
    NCT01260129
    Conditions
    Benign Prostatic Hypertrophy
    Interventions
    Silodosin; Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-10
    Enrolment
    424

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hypertrophy
    InterventionSilodosin; Silodosin
    PhasePhase 4
    Registry statusCompleted

  • Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

    NCT01435954 · start 2010-08

    Registered record
    Registry ID
    NCT01435954
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Early combination therapy; Delayed combination therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-03
    Enrolment
    13,551

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionEarly combination therapy; Delayed combination therapy
    PhaseNot recorded
    Registry statusCompleted

  • Study of Silodosin to Facilitate Passage of Urinary Stones

    NCT01144949 · start 2010-06

    Registered record
    Registry ID
    NCT01144949
    Conditions
    Ureteral Calculi; Kidney Stones; Urolithiasis
    Interventions
    silodosin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2012-07
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteral Calculi; Kidney Stones; Urolithiasis
    Interventionsilodosin; placebo
    PhasePhase 2
    Registry statusCompleted

  • Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence

    NCT01390870 · start 2009-05

    Registered record
    Registry ID
    NCT01390870
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI or AB or Combination Therapy (5ARI + AB)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI or AB or Combination Therapy (5ARI + AB)
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

    NCT00793819 · start 2009-01

    Registered record
    Registry ID
    NCT00793819
    Conditions
    Nocturia; Prostatic Hyperplasia
    Interventions
    silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-10
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturia; Prostatic Hyperplasia
    Interventionsilodosin
    PhasePhase 2
    Registry statusCompleted

  • Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

    NCT00740779 · start 2008-09

    Registered record
    Registry ID
    NCT00740779
    Conditions
    Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
    Interventions
    Silodosin 8 mg; Placebo; Silodosin 4 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2009-10
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
    InterventionSilodosin 8 mg; Placebo; Silodosin 4 mg
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

    NCT00359905 · start 2006-05

    Registered record
    Registry ID
    NCT00359905
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Silodosin; Tamsulosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2008-01
    Enrolment
    1,228

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSilodosin; Tamsulosin; Placebo
    PhasePhase 3
    Registry statusCompleted